Altimmune Inc [NASDAQ: ALT] traded at a high on Wednesday, posting a 7.94 gain after which it closed the day’ session at $7.07. The results of the trading session contributed to over 4110941 shares changing hands. Over the past one week, the price volatility of
Altimmune Inc [NASDAQ: ALT] loss -6.38% or -0.48 points to close at $7.04 with a heavy trading volume of 3629944 shares. The daily chart for ALT points out that the company has recorded 156.00% gains over the past six months. If we look at the
Altimmune Inc [NASDAQ: ALT] stock went on an upward path that rose over 4.87% on Thursday, amounting to a one-week price decrease of less than -5.62%. The company report on March 27, 2024 at 7:00 AM that Altimmune Announces Positive Lean Mass Preservation Data for
Altimmune Inc [NASDAQ: ALT] closed the trading session at $8.90. The company report on March 27, 2024 at 7:00 AM that Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results. Body composition study showed lean
Altimmune Inc [NASDAQ: ALT] stock went on an upward path that rose over 2.77% on Wednesday, amounting to a one-week price decrease of less than -4.82%. The company report on March 27, 2024 at 7:00 AM that Altimmune Announces Positive Lean Mass Preservation Data for
Altimmune Inc [NASDAQ: ALT] closed the trading session at $9.11. The company report on March 20, 2024 at 7:30 AM that Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024. Altimmune management will host a
Altimmune Inc [NASDAQ: ALT] closed the trading session at $10.87. The company report on January 2, 2024 at 7:30 AM that Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024. Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today
Altimmune Inc [NASDAQ: ALT] closed the trading session at $10.03. The company report on January 2, 2024 at 7:30 AM that Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024. Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today
Altimmune Inc [NASDAQ: ALT] gained 23.04% or 2.12 points to close at $11.32 with a heavy trading volume of 17605276 shares. The company report on January 2, 2024 at 7:30 AM that Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January
Altimmune Inc [NASDAQ: ALT] stock went on a downward path that fall over -18.65% on Tuesday, amounting to a one-week price decrease of less than -20.49%. The company report on January 2, 2024 at 7:30 AM that Altimmune Announces Presentation of Pemvidutide Clinical Data at
© 2024, Powered by Smart TechOne
